Prior work has shown the loss of the tumor suppressor PTEN to be associated with poor responses to PD‐1 blockade in patients with melanoma, uterine sarcoma, and mTNBC,19 and that partial PTEN deletions associate with worse OS in breast cancer.37 The gene discussed is PTEN; the disease is melanoma.